P
Phio Pharmaceuticals Corp. (PHIO)
NCM – Real Time Price. Currency in USD
1.10
+0.02 (1.85%)
At close: May 12, 2026, 4:00 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
1.10
+0.02 (1.85%)
At close: May 12, 2026, 4:00 PM EDT
Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-center Phase 1b dose-escalating clinical trials; PH-894, an INTASYL compound that is designed to specifically silence BRD4, a protein that controls gene expression in both T cells and tumor cells in preclinical studies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was founded in 2003 and is based in King Of Prussia, Pennsylvania.
| Name | Position |
|---|---|
| Dr. Jennifer Phillips Pharm.D. | Senior Vice President of Regulatory & Corporate Affairs |
| Mr. Robert J. Bitterman | President, CEO & Chairman |
| Ms. Linda M. Mahoney | Senior Vice President of Development |
| Ms. Lisa C. Carson | CFO, Principal Accounting Officer and VP of Finance & Administration |
| Date | Type | Document |
|---|---|---|
| 2026-05-07 | 8-K | phio20260331_8k.htm |
| 2026-05-07 | 10-Q | phio20260331_10q.htm |
| 2026-04-08 | 8-K | phio20260402_8k.htm |
| 2026-03-30 | 8-K | phio20260326_8k.htm |
| 2026-03-05 | 8-K | phio20251215_8k.htm |
| 2026-02-18 | 8-K | phio20260216_8k.htm |
| 2026-02-10 | 8-K | phio20260206_8k.htm |
| 2026-01-20 | 8-K | phio20260113_8k.htm |
| 2025-12-23 | 8-K | phio20251222_8k.htm |
| 2025-12-01 | CORRESP | filename1.htm |